Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability

Cellular and Molecular Gastroenterology and Hepatology

Volumn 1, Issue 2, 2015, Pages 222-232.e2

  Luther, Jay ^a   Garber, John J ^a   Khalili, Hamed ^a   Dave, Maneesh ^b   Bale, Shyam Sundhar ^a   Jindal, Rohit ^a   Motola, Daniel L ^a   Luther, Sanjana ^a   Bohr, Stefan ^a   Jeoung, Soung Won ^a   Deshpande, Vikram ^a   Singh, Gurminder ^c   Turner, Jerrold R ^c   Yarmush, Martin L ^a   Chung, Raymond T ^a   Patel, Suraj J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Meta Analysis; Myosin Light Chain Kinase; Steatosis; Tight Junctions

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLINE; METHIONINE; MYOSIN LIGHT CHAIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; FATTY LIVER; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; KUPFFER CELL; LIVER CELL; LIVER CELL DAMAGE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SYSTEMIC CIRCULATION; TIGHT JUNCTION;

EID: 84928969190     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2015.01.001     Document Type: Article

References (48)

1. Szczepaniak L.S., Nurenberg P., Leonard D., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005, 288:E462-E468.
2. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121:91-100.
3. Gabele E., Dostert K., Hofmann C., et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. JHepatol 2011, 55:1391-1399.
4. Henao-Mejia J., Elinav E., Jin C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
5. Pendyala S., Neff L.M., Suarez-Farinas M., Holt P.R. Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis. Am J Clin Nutr 2011, 93:234-242.
6. Zhu L., Baker S.S., Gill C., et al. Characterization of gut microbiome in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013, 57:601-609.
7. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
8. Higgins J.P., Thompson S.G., Deeks J.J. Measuring inconsistency in meta-analysis. BMJ 2003, 327:557-560.
9. Wells GA, Shea B, O'Connell D, etal. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Health Research Institute, nd. Available at:. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
10. Sterne J.A., Gavaghan D., Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. JClin Epidemiol 2000, 53:1119-1129.
11. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalocholic fatty liver disease. Hepatology 2005, 41:1313-1321.
12. Napolitano L.M., Koruda M.J., Meyer A.A., Baker C.C. The impact of femur fracture with associated soft tissue injury on immune function and intestinal permeability. Shock 1996, 5:202-507.
13. Clayburgh D.R., Barrett T.A., Tang Y., et al. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell-activation-induced diarrhea invivo. JClin Invest 2005, 115:2702-2715.
14. King K.R., Wang S., Irimia D., et al. Ahigh-throughput microfluidic real-time gene expression living cell array. Lab Chip 2007, 7:77-85.
15. McMullen M., Pritchard M., Nagy L. Isolation of Kupffer cells from rates fed chronic ethanol. Alcohol: methods and protocols 2008, 199-212. Humana Press, Totowa, NJ. L.E. Nagy (Ed.).
16. Sahai A., Pan X., Paul R., et al. Roles of phosphatidylinositol 3-kinase and osteopontin in steatosis and aminotransferase release by hepatocytes treated with methionine-choline-deficient medium. Am J Physiol Gastrointest Liver Physiol 2006, 291:G55-G62.
17. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
18. Farhadi A., Gundlapalli S., Shaikh M., et al. Susceptibility togut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008, 28:1026-1033.
19. Miele L., Valenza V., La Torre G., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49:1877-1887.
20. Volynets V., Kuper M.A., Strahl S., et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2012, 57:1932-1941.
21. Giorgio V., Miele L., Principessa L., et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis 2014, 46:556-560.
22. van Wijck K., Bessems B.A., van Eijk H.M., et al. Polyethylene glycol versus dual sugar assay for gastrointestinal permeability analysis: is it time to choose?. Clin Exp Gastroenterol 2012, 5:139-150.
23. Miura K., Kodama Y., Inokucki S., et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice. Gastroenterology 2010, 139:323-334.
24. Mas E., Danjoux M., Garcia V., et al. IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS ONE 2009, 4:e7929.
25. Marchiando A.M., Shen L., Graham W.V., et al. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation invivo. JCell Biol 2010, 189:111-126.
26. Su L., Nalle S.C., Shen L., et al. TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology 2013, 145:407-415.
27. Bardella M.T., Valenti L., Pagliari C., et al. Searching for coeliac disease in patients with non-alcoholic fatty liver disease. Dig Liver Dis 2004, 36:333-336.
28. McGowan C.E., Jones P., Long M.D., Barritt A.S. Changing shape of disease: nonalcoholic fatty liver disease in Crohn's disease-a case series and review of the literature. Inflamm Bowel Dis 2012, 18:49-54.
29. Reddy S.K., Zhan M., Alexander H.R., El-Kamary S.S. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol 2013, 19:8301-8311.
30. Ma Y.Y., Li L., Yu C.H. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013, 19:6911-6918.
31. Du Plessis J., Vanheel H., Janssen C.E., et al. Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. JHepatol 2013, 58:1125-1132.
32. Seki E., Schanbl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. JPhysiol 2012, 590:447-458.
33. Crespo J., Cayon A., Fernandez-Gil P., et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34:1158-1163.
34. Alaaeddine N., Sidaoui J., Hilal G., et al. TNF-α messenger ribonucleic acid (mRNA) in patients with nonalcoholic steatohepatitis. Eur Cytokine Netw 2012, 23:107-111.
35. Bahccioglu I.H., Yalniz M., Ataseven H., et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 2005, 52:1549-1553.
36. Zolotarevsky Y., Hecht G., Koutsouris A., et al. Amembrane-permeant peptide that inhibits mlc kinase restores barrier function in invitro models of intestinal disease. Gastroenterology 2002, 123:163-172.
37. Wang F., Graham W.V., Wang Y., et al. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 2005, 166:409-419.
38. Al-Sadi R., Guo S., Ye D., et al. Mechanism of IL-1β modulation of intestinal epithelial barrier involves p38 kinase and activating transcription factor-2 activation. JImmunol 2013, 190:6596-6606.
39. Lee J.K., Bettencourt R., Brenner D., et al. Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study. PLoS ONE 2012, 7:e34218.
40. Suzuki T., Yoshinaga N., Tanabe S. Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. JBiol Chem 2011, 286:31263-31271.
41. Csak T., Pillai A., Ganz M., et al. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis. Liver Int 2014, 34:1402-1413.
42. Pena A.D., Leclercq I., Field J., et al. NF-κB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005, 129:1663-1674.
43. Tomita K., Tamiya G., Ando S., et al. Tumour necrosis factor signalling through activation of Kupffer cells plays an essential role in liver fibrosis of nonalcoholic steatohepatitis in mice. Gut 2006, 55:415-424.
44. Koca S.S., Bahcecioglu I.H., Poyrazoglu O.K., et al. The treatment with antibody to TNF-alpha reduces the inflammation, necrosis, and fibrosis in the non-alcoholic steatohepatitis induced by the methionine-and choline-deficient diet. Inflammation 2008, 31:91-98.
45. Pinto Lde F., Compri C.M., Fornari J.V., et al. The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice. Liver Int 2010, 30:603-610.
46. Campanati A., Ganzetti G., Di Sario A., et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. JGastroenterol 2013, 48:839-846.
47. Chen P., Starkel P., Turner J.R., et al. Dysbiosis-induced intestinal inflammation activates TNFRI and mediates alcoholic liver disease in mice. Hepatology 2014, Published online. http://dx.doi.org/10.1002/hep.27489.
48. 51Cr-EDTA. Am J Gastroenterol 1985, 80:770-773.